1Weiss SA, Jolly N. Practical considerations of percutaneous ventricular assist devices. J Invasive Cardiol, 2012,24: 25-31.
2Foreman RD, Linderoth B, Ardell JL, et al. Modulation of in-trinsic cardiac neurons by spinal cord stimulation:Implications for its therapeutic use in angina pectoria. Cardiovasc Res, 2000,47 : 367-375.
3Lopshire JC,Zhou X,Dusa C,et al. Spinal cord stimulation in dogs with post-infarction heart failure. Circulation, 2009,120 286-294.
4Hedman M, Muona K, Hedman A, et al. Eight year safety fol- low-up of coronary artery disease patients after local intracor- onary VEGF gene transfer. Gene Ther,2009,16:629 634.
5Rissanen TT, Yla-Herttuala S. Current status of cardiovascu- lar gene therapy. Mol Ther, 2007,15 : 1233-1247.
6Jaski BE,Jessup ML, Mancini DM, et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac dis- ease(CUPID Trial). Journal of cardiac failure,2009,15: 171-181.
7Pittenger MF, Martin BJ. Mesenehymal stem cells and their potential as cardiac therapeutics. Circulation Research, 2004, 95:9 20,.
8Uecelli A, Moretta L, Pistoia V. Immunoregulatory function of mesenehymal stem cells. Eur J Immunol, 2006,36: 2566- 2577.
9Assmus B, Roll A, Erbs S, et al. REPAIRAMI investigators. Clinical outcome 2 years after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial in farction. Circ Heart Fail, 2010,3: 89 96.
10Kang S, Yang YJ, Li C J, et al. Effects of intracoronary autolo- gous bone marrow ceils on left ventricular function in acute myocardial infarction: A systematic review and metwanalysis for randomized controlled trials. Coron Artery Dis, 2008,19 327-335.
